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Abstract
Background: There appears to be a significant increase in the prevalence rate of autism. Reasons
for the increase are unknown, however, there is a substantial body of evidence that suggests the
etiology involves infections of the pregnant mother or of a young child. Most infections result in
fever that is routinely controlled with antipyretics such as acetaminophen. The blocking of fever
inhibits processes that evolved over millions of years to protect against microbial attack. Immune
mechanisms in the central nervous system are part of this protective process.
Hypothesis:  The blockage of fever with antipyretics interferes with normal immunological
development in the brain leading to neurodevelopmental disorders such as autism in certain
genetically and immunologically disposed individuals.
Testing the hypothesis: Epidemiological studies to determine associations between the use of
antipyretics and neurodevelopmental disorders should be undertaken. Biochemical tests will
involve the examination of fluids/serum by mass spectrometry and the determination of cytokine/
chemokine levels in serum and cell culture fluids after stimulation with fever-inducing molecules
from bacteria, viruses and yeast. Postmortem brain can be examined by immunohistochemistry or
other methods such as fluorescent in situ hybridization (FISH) to determine altered expression
levels of chemokines/cytokines and other molecules.
Implications of the hypothesis: 1) The use of antipyretics during pregnancy or in young children
may be reserved for more severe fevers. 2) The perplexing genetic findings in autism may be better
understood by categorizing genes along functional pathways. 3) New treatments based on immune,
cell, pharmacological or even heat therapies may be developed.
Background
According to epidemiological studies, autism, a neurode-
velopmental disorder, is increasing in the pediatric popu-
lation [1]. In 1966 the prevalence rate was 4–5/10,000
births [2], while two recent studies show prevalence rates
of 14.9/10,000 [1] and 34/10,000 [3]. Although there is
no question that more clinical cases are being detected,
the increase in prevalence of autism is in dispute as diag-
nostic practices have changed over the years and this
heightened awareness has changed the evaluation of pre-
viously unrecognized cases [4]. Increased services have
also contributed to the rise as clinicians are inclined to get
individuals into autism programs that can help remarka-
bly. Despite these considerations, there is still a concern
about a real increase in the prevalence rate.
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In 1943, Kanner [5] described autism as a neurodevelop-
mental disorder with impairments in social interactions,
restricted stereotyped interests, and abnormalities in ver-
bal and nonverbal behavior. Little is known about the eti-
ology, and the diagnosis of autism is done by behavioral
criteria as no biomarkers have yet been identified. There is
a strong familial component to autism [6], and etiologies
based on infectious [7], autoimmune [8–11], and
cytokine factors [12,13] have been proposed.
About 40% of parents with autistic children report that
their seemingly normal children experienced develop-
mental regression after being vaccinated. However, the
theory of vaccines or adjuvants being involved in the eti-
ology [14] has little support as epidemiological studies
have failed to show an association with the measles,
mumps, and rubella (MMR) vaccine [15–17] and autism.
It has been reported that 43% of mothers with an autistic
child experienced upper respiratory tract, influenza-like,
urinary, or vaginal infections during pregnancy compared
to only 26% of control mothers [10]. Studies show that in
rats, maternal exposure to infection alters proinflamma-
tory cytokine levels in the fetal environment, including
the brain; it has been proposed that these changes may
have a significant impact on the developing brain [18,19].
This suggests that certain cases of autism may be a sequela
of pathogenic infections, especially those of a viral origin
[20–23].
There is no overt pathological lesion in autism, however,
subtle abnormalities in the cerebellum, hippocampal
fields CA1–CA4, entorhinal cortex, amygdala, behavioral
differences and imbalances in cytokines and brain growth
factors suggest that abnormal brain development is
important in the pathogenesis [24–26].
Pathological infections, including vaccinations, com-
monly result in fever. For example, 50–60% of young chil-
dren develop fever after receiving the MMR vaccine [27].
Fever is rarely harmful and only extremely high fevers of
42.2C (108F) may cause brain damage. However, fevers of
41C (106F) should get immediate medical attention to
examine the patient for severe infection [28].
Fever is defined as an increase in the normal set point of
body temperature. During the rising phase of fever, nor-
mal body temperature is below the new set point and the
body, being hypothermic, uses several heat conserving
and heat generating physiological reflexes, as well as
behavioral responses, to raise body temperature. The
breaking of fever results in a variety of heat-losing reflexes
and behavioral responses to lower body temperature.
There are two related fever pathways. The intraperitoneal
injection of lipopolysaccharide (LPS), a potent pyrogen,
results in the production of various cytokines from organs
in the viscera. Cytokines are polypeptides that are
involved in inflammation, immune activation, cell differ-
entiation and cell death. These groups of polypeptides
include interleukins, interferons, tumor necrosis factors,
chemokines and growth factors. They generally have little
or no known function in healthy tissue, but can be
induced in a very rapid manner in response to tissue
injury, inflammation or infection. A signal from IL-1β is
thought to initiate afferent information traveling from the
vagus nerve to the hypothalamus to increase hypotha-
lamic IL-1β. This in turn causes an increase in hypotha-
lamic IL-6, which raises the thermoregulatory set point.
This pathway is mediated via prostaglandins and can be
blocked by cyclooxygenase inhibitors (antipyretics).
These two cytokines are also important in inflammation
and are commonly labeled as proinflammatory cytokines.
The second fever pathway, also initiated in the hypothala-
mus by afferent signals from the vagus nerve, is mediated
by locally produced macrophage inflammatory protein-1
(MIP-1), a chemokine. MIP-1 appears to act directly on
the anterior hypothalamus via a non-prostaglandin mech-
anism and is not blocked by antipyretics [29].
Fever is metabolically expensive: every 1°C rise in temper-
ature increases the metabolic rate approximately 10%
[30]. It stands to reason that a defense mechanism that
evolved over millions of years and is so costly in terms of
energy must be important. Numerous studies have shown
that fever enhances the immune response by increasing
mobility and activity of white cells, stimulating the pro-
duction of interferon, causing the activation of T-lym-
phocytes, and indirectly reducing plasma iron
concentrations [29–32]. Antiviral and antibacterial prop-
erties of interferon are also increased at febrile tempera-
tures [33,34]. A decreased morbidity and mortality rate
has been associated with fever in a variety of infections
[35–39]. Newborn animals infected with a variety of
viruses have a higher survival rate when febrile [40]. The
use of antipyretics to suppress fever results in an increased
mortality rate in bacterially infected rabbits [41] and an
increase in influenza virus production in ferrets [42].
Brain hyperthermia markedly exacerbates neuronal injury
[43]. There is anecdotal evidence that children with
autism show behavioral improvement when febrile (D.
Odell, personal communications, 2003).
Sequestering fever during pregnancy may have effects on
the fetus. Goetzl et al. [44] have shown that the treatment
of epidural fever with acetaminophen significantly
decreased maternal and fetal serum IL-6 levels at the time
of birth. This may be significant, as it appears that theBMC Pediatrics 2003, 3 http://www.biomedcentral.com/1471-2431/3/9
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fetus is incapable of producing IL-6 at the time of birth
and is dependent on maternal IL-6 [45]. Although the
expression of cytokines in the CNS is very low, brain cells
can produce specific cytokines as well as cytokine recep-
tors under certain conditions [19]. For example, IL-6 and
its specific receptor (IL-6R) are expressed on neurons and
glial cells including astrocytes. There is mounting evi-
dence that IL-6 is important in the development, differen-
tiation, regeneration and degeneration of neurons in the
central nervous system [46]. It is known that IL-6 pro-
motes the differentiation of precursor cells to astrocytes
and functions as a differentiation factor for neurons of the
peripheral and central nervous system. IL-6 and sIL-6R
have also been shown to be important in regulating the
expression of specific neurotrophins in astrocytes [46].
Pathological conditions in the CNS have been observed in
transgenic mice that have astrocyte-targeted expression of
IL-6. High levels of IL-6 in these mice correlate with astro-
cytosis, microgliosis, angiogenesis and the up-regulation
of several inflammatory genes including IL-1 α/β, TNFα,
GFAP, ICAM, and complement C3. Transgenic mice
expressing TNFα and INF-α also displayed significant
neurological changes [47]. Projects such as these suggest
that normal brain development requires a delicate bal-
ance of different cytokines.
Ozato et al. [48] described the response of cell-surface
toll-like receptors (TLRs) upon binding to microbial path-
ogens. There are at least 10 TLRs that recognize ligands
from bacteria, viruses, yeast, and nucleic acids from
viruses. There is a high binding specificity of the different
TLRs for each microbial structure referred to as pathogen-
associated molecular patterns (PAMPs) [48]. The best
studied is TLR4 that binds LPS from gram-negative bacte-
ria. The ligation of LPS to cell surface TLR4 initiates a sig-
nal cascade that results in the activation of intracellular
nuclear factor kappa beta (NF6B) and the transcription of
numerous genes involved in immune responses. This sig-
naling pathway appears to be common to all the TLRs
whether the PAMPs originate from bacteria, virus, or
yeast. TLRs are mainly expressed myeloid lineage cells
including macrophages, granulocytes and dendritic cells.
The central nervous system exhibits a similar immune
reaction to pathogenic infection. There is a broad expres-
sion of TLRs in human brain astrocytes, oligodendrocytes
and microglia [49]. Astrocytes and oligodendrocytes
express mRNA for TLR2 that recognizes fungal, gram-pos-
itive and mycobacterial components and TLR3 that recog-
nize double-stranded RNA. Microglia cells express mRNA
for a wide range of TLR family members (TLR2, TLR3,
TLR4, TLR5, TLR6, TLR7, TLR8 and TLR9) much like other
cells of the monocytic lineage [49]. The binding of LPS to
TLR on microglia cells (brain macrophage) leads to the
innate expression of cytokines, chemokines, extracellular
matrix proteins, proteolytic enzymes, and complement
proteins in the brain parenchyma [50,51]. It is also well
established that glial cells participate in innate immune
responses in human CNS [49].
Fever is generally considered harmful by physicians and is
treated with antipyretics as it may lead to febrile seizures,
stupor, dehydration, increased breathing, discomfort, and
tachycardia [52]. It is a common practice to treat even
low-grade fevers of 101–102F with antipyretics. Home use
of antipyretics upon the first signs of a fever is also com-
mon. These behaviors have lead to the ubiquitous use of
aspirin, acetaminophen, nimesulide, and ibuprofen,
which control temperature by inhibiting prostaglandin
synthesis in the hypothalamus. Aspirin is not currently
recommended in the pediatric population due to an asso-
ciation with Reye's syndrome [53].
Acetaminophen (AP), the most widely used medication,
is considered safe when used at pharmacological doses.
High doses of AP can lead to liver failure and death with-
out proper emergency treatment. Although the hepato-
toxic actions of AP have been extensively researched, there
is evidence that it is also an immunosuppressive agent.
Suppression of the delayed hypersensitivity response and
mixed lymphocyte reaction occur in mice fed AP [54]. It
has recently been shown that AP added directly to spleno-
cyte cultures inhibited the in vitro antibody response with-
out affecting cell viability [55]. Other immune effects
include an impairment of TNFα release [56] and a 10–20-
fold increase of monocyte chemoattractant protein (MCP-
1) and chemokine receptor (CCR) from liver Kupffer cells
(macrophages) [57]. These studies suggest that the AP
directly affects immune cells and is not a secondary
response to AP-hepatitis.
Presentation of the hypothesis
The premise of this theory is that the blockage of fever
with antipyretics interferes with normal immunological
development in the brain, leading to neurodevelopmen-
tal disorders in certain genetically and immunologically
disposed individuals. The effects may occur in utero or at
a very young age when the immune system is rapidly
developing. Maternal infection is a risk factor for neurode-
velopmental disorders including autism [20–23]. It has
been shown that in rats, maternal exposure to infection
alters proinflammatory cytokine levels in the fetal envi-
ronment, including the brain; it has been proposed that
these changes may have a significant impact on the devel-
oping brain [18,19]. Acetaminophen also interferes with
IL-6 [44] levels as well as the release of TNFα [56], the
same proinflammatory cytokines necessary for brain
development.BMC Pediatrics 2003, 3 http://www.biomedcentral.com/1471-2431/3/9
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Testing the hypothesis
The experimental avenues below can be used to test the
theory:
1) Epidemiological studies can be undertaken to deter-
mine any association between the use of antipyretics and
neurodevelopmental disorders.
2) Peripheral blood cells from subjects with neurodevel-
opmental disorders and controls can be examined in cul-
ture for chemokine/cytokine production after stimulation
with bacterial, viral, or yeast PAMPs. The incubation of
isolated white blood cells with bacterial or viral compo-
nents (LPS, unmethylated DNA, dsRNA) that are known
to increase cytokine expression may be useful to deter-
mine if there are genetically encoded differences in cells
from subjects with autism and age- and sex-matched con-
trols. It has been shown that the administration of low
dose IL-1β to mice at birth suggests that long-lasting and
perhaps permanent alterations occur in the CNS and
peripheral neurotransmitter systems [58]. It would be
important to know if individuals with autism are prone to
be low or high producers of certain cytokines like IL-1β or
IL-6.
3) The expression of chemokines/cytokines such as IL-1β
and IL-6 can be examined in postmortem brain by immu-
nohistochemistry, FISH, western/northern blotting or
other molecular methods. These two cytokines play semi-
nal roles in fever and are also important in the proinflam-
matory response. It has recently been shown that IL-1β,
IL-6 and TNFα decrease in vitro survival of certain neu-
rons and play important roles in the normal development
of neurons including proliferation, survival, differentia-
tion, axodendritic outgrowth and synaptic regulation
[59].
4) Serum/plasma samples can be evaluated by analytical
methods in an attempt to detect biomarkers for autism.
Significant advances in mass spectrometry have been
made in examining complex samples like serum for
biomarkers for disease [60]. We have preliminary data
examining plasma from subjects with autism and age-and
sex-matched control samples by time-of-flight mass spec-
trometry. Examination of this data by multivariate analy-
sis suggests that plasma from subjects with autism may
have a unique peptide/protein profile.
5) Animal models can be tested in vivo to determine the
neurodevelopmental effects of fever treatment. For exam-
ple, brain tissue can be examined for cytokine/chemokine
differences in mice treated/untreated with antipyretics
after inducing fever with LPS.
Implications of the hypothesis
Several important changes may result from studies
designed to test the theory:
1) The use of antipyretics during pregnancy or in young
children may be reserved for more severe fevers.
2) Many of the perplexing genetic findings in autism may
be better understood by categorizing genes along func-
tional pathways. For example, the genes for TLR5, TLR9,
TLR1, TLR4, and TLR7 are on different chromosomes
(1,3,4,9, and X respectively). The binding of the respective
ligand to a TLR causes the activation of a common tran-
scriptional factor NF6B that results in the transcription of
numerous immune related genes. This example clearly
illustrates that genetic defects on different chromosomes
may have a common result.
3) The discovery of specific immune defects may suggest
new therapies for neurodevelopmental disorders. These
treatments may be based on immune, cell, pharmacolog-
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